A multiplexed screening method for agonists and antagonists of the estrogen receptor protein

Analytical and Bioanalytical Chemistry

Volumn 403, Issue 5, 2012, Pages 1373-1384

  Li, Zhonghui ^a   Yan, Ming ^b   Li, Zhoumin ^a   Vuki, Maika ^c   Wu, Dan ^d   Liu, Fei ^d   Zhong, Wenying ^b   Zhang, Luyong ^b   Xu, Danke ^a  

^a NANJING UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c UNIVERSITY OF GUAM   (Guam)

^d TSINGHUA UNIVERSITY   (China)

Author keywords

Estrogen receptor; High throughput screening; Protein microarray; Protein drug interaction

Indexed keywords

DRUG TARGETS; DRUG-SCREENING; ESTROGEN RECEPTOR; FLUORESCENCE POLARIZATION; GLASS SLIDES; HIGH-THROUGHPUT; HIGH-THROUGHPUT SCREENING; NATURAL PRODUCTS; PATHOLOGICAL FUNCTIONS; PROTEIN MICROARRAY; PROTEIN-DRUG INTERACTION; SCREENING METHODS; SYNTHETIC COMPOUNDS; TAMOXIFEN;

ALDEHYDES; BIOASSAY; BIOCHIPS; DRUG INTERACTIONS; LIGANDS; MASS SPECTROMETRY;

PROTEINS;

ANTIESTROGEN; ESTRADIOL DERIVATIVE; ESTROGEN RECEPTOR; LIGAND; RALOXIFENE; TAMOXIFEN;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG POTENTIATION; EVALUATION; HUMAN; KINETICS; METABOLISM; METHODOLOGY; PROTEIN BINDING; PROTEIN MICROARRAY;

ESTRADIOL CONGENERS; ESTROGEN ANTAGONISTS; HUMANS; KINETICS; LIGANDS; PROTEIN ARRAY ANALYSIS; PROTEIN BINDING; RALOXIFENE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 84862787623     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-012-5933-7     Document Type: Article

References (53)

1. Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA (2006) International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 58 (4):773-781. doi:10.1124/pr.58.4.8 (Pubitemid 44833745)
2. White R, Lees JA, Needham M, Ham J, Parker M(1987) Structural organization and expression of the mouse estrogen receptor. Mol Endocrinol 1(10):735-744 (Pubitemid 17166939)
3. Fitzpatrick SL, Funkhouser JM, Sindoni DM, Stevis PE, Deecher DC, Bapat AR, Merchenthaler I, Frail DE (1999) Expression of estrogen receptor-beta protein in rodent ovary. Endocrinology 140 (6):2581-2591. doi:10.1210/en.140.6. 2581 (Pubitemid 32245136)
4. Kuiper G, Enmark E, PeltoHuikko M, Nilsson S, Gustafsson JA (1996) Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93(12):5925-5930. doi:10.1073/pnas.93.12.5925 (Pubitemid 26190778)
5. Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS (1997) Tissue distribution and quantitative analysis of estrogen receptoralpha (ER alpha) and estrogen receptor-beta (ER beta) messenger ribonucleic acid in the wild-type and ER alpha-knockout mouse. Endocrinology 138(11):4613-4621. doi:10.1210/en.138. 11.4613 (Pubitemid 27460895)
6. Yaghmaie F, Saeed O, Garan SA, Freitag W, Timiras PS, Sternberg H (2005) Caloric restriction reduces cell loss and maintains estrogen receptor-alpha immunoreactivity in the pre-optic hypothalamus of female B6D2F1 mice. Neuroendocrinol Lett 26(3):197-203 (Pubitemid 40975096)
7. Babiker FA, De Windt LJ, van Eickels M, Grohe C, Meyer R, Doevendans PA (2002) Estrogenic hormone action in the heart: regulatory network and function. Cardiovasc Res 53(3):709-719. doi:10.1016/s0008-6363(01)00526-0 (Pubitemid 34175263)
8. Maass H, Engel B, Trams G, Nowakowski H, Stolzenbach G (1975) Steroid-hormone receptors in human breast-cancer and clinical significance. J Steroid Biochem Mol Biol 6(5):743-749. doi:10.1016/0022-4731(75)90062-x
9. Gasparini G, Pozza F, Harris AL (1993) Evaluating the potential usefulness of new prognostic and predictive indicators in nodenegative breast-cancer patients. J Natl Cancer Inst 85(15):1206-1219. doi:10.1093/jnci/85.15.1206 (Pubitemid 23223526)
10. May E, Mouriesse H, Maylevin F, Contesso G, Delarue JC (1989) A new approach allowing an early prognosis in breast-cancer: the ratio of estrogen receptor (ER) ligand binding activity to the ERspecific mRNA level. Oncogene 4(8):1037-1042 (Pubitemid 19202822)
11. Ascenzi P, Bocedi A, Marino M (2006) Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med 27(4):299-402 (Pubitemid 44255847)
12. Bourguet W, Germain P, Gronemeyer H (2000) Nuclear receptor ligand-binding domains three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci 21(10):381-388. doi:10.1016/s0165-6147(00)01548-0
13. Riggs BL, Hartmann LC (2003) Drug therapy: selective estrogenreceptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348(7):618-629 (Pubitemid 36210865)
14. Grilli S (2006) Tamoxifen (TAM): the dispute goes on. Ann Ist Super Sanita 42(2):170-173 (Pubitemid 44562794)
15. Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, Salvioni A, Travaglini R, Oliviero P, D'Aiuto G, Gulisano M, Gucciardo G, del Turco MR, Pizzichetta MA, Conforti S, Bonanni B, Boyle P, Veronesi U, Italian Tamoxifen Study Group (2005) Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 111(5):650-656. doi:10.1161/01.cir.0000154545.84124.ac (Pubitemid 40216494)
16. Osman KA, Osman MM, Ahmed MH (2007) Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going? Expert Opin Drug Saf 6(1):1-4. doi:10.1517/14740338.6.1.1 (Pubitemid 46138602)
17. Bender CM, Sereika SM, Brufsky AM, Ryan CM, Vogel VG, Rastogi P, Cohen SM, Casillo FE, Berga SL (2007) Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 14(6):995-998. doi:10.1097/gme.0b013e318148b28b (Pubitemid 350098658)
18. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A, Group ObotAT (2006) Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 100(3):273-284 (Pubitemid 44707921)
19. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355(2):125-137. doi:10.1056/NEJMoa062462 (Pubitemid 44050394)
20. Powell E, Huang SX, Xu Y, Rajski SR, Wang YD, Peters N, Guo S, Xu HE, Hoffmann FM, Shen B, Xu W (2010) Identification and characterization of a novel estrogenic ligand actinopolymorphol A. Biochem Pharmacol 80(8):1221-1229. doi:10.1016/j.bcp. 2010.06.030
21. De S, Macara IG, Lannigan DA (2005) Novel biosensors for the detection of estrogen receptor ligands. J Steroid Biochem Mol Biol 96(3-4):235-244 (Pubitemid 41080504)
22. Gunther JR, Du YH, Rhoden E, Lewis I, Revennaugh B, Moore TW, Kim SH, Dingledine R, Fu HA, Katzenellenbogen JA (2009) A set of time-resolved fluorescence resonance energy transfer assays for the discovery of inhibitors of estrogen receptor-coactivator binding. J Biomol Screen 14(2):181-193. doi:10.1177/1087057108329349
23. Huttunen R, Shweta ME, Lahdenranta M, Virta P, Hanninen P, Harma H (2011) Single-label time-resolved luminescence assay for estrogen receptor-ligand binding. Anal Biochem 415(1):27-31. doi:10.1016/j.ab.2011.03.038
24. Visegrady A, Bielik A, Keseru GM (2005) Fluorescence anisotropybased automated high throughput screening of estrogen receptor beta ligands. FEBS J 272:489-489
25. Parker GJ, Law TL, Lenoch FJ, Bolger RE (2000) Development of high throughput screening assays using fluorescence polarization: nuclear receptor-ligand-binding and kinase/phosphatase assays. J Biomol Screen 5(2):77-88. doi:10.1177/108705710000500204 (Pubitemid 30243877)
26. Tirri M, Huttunen R, Toivonen J, Harkonen P, Soini J, Hanninen P (2005) Two-photon excitation in fluorescence polarization receptor-ligand binding assay. J Biomol Screen 10(4):314-319. doi:10.1177/1087057104273334 (Pubitemid 40800559)
27. Choi Y, van Breemen RB (2008) Development of a screening assay for ligands to the estrogen receptor based on magnetic microparticles and LC-MS. Comb Chem High Throughput Screen 11(1):1-6
28. Ng W, Dai JR, Slon-Usakiewicz JJ, Redden PR, Pasternak A, Reid N (2007) Automated multiple ligand screening by frontal affinity chromatography-mass spectrometry (FAC-MS). J Biomol Screen 12(2):167-174. doi:10.1177/ 1087057106297567 (Pubitemid 46364426)
29. Yoshino T, Kato F, Takeyama H, Nakai M, Yakabe Y, Matsunaga T (2005) Development of a novel method for screening of estrogenic compounds using nano-sized bacterial magnetic particles displaying estrogen receptor. Anal Chim Acta 532(2):105-111. doi:10.1016/j.aca.2004.10.074 (Pubitemid 40330921)
30. Sun ZH, Fu XL, Zang L, Yang XL, Liu FZ, Hu GX (2004) A protein chip system for parallel analysis of multi-tumor markers and its application in cancer detection. Anticancer Res 24 (2C):1159-1165
31. Combaret V, Bergeron C, Brejon S, Iacono I, Perol D, Negrier S, Puisieux A (2005) Protein chip array profiling analysis of sera from neuroblastoma patients. Cancer Lett 228(1-2):91-96. doi:10.1016/j.canlet.2004.12.053 (Pubitemid 41188429)
32. MacBeath G, Schreiber SL (2000) Printing proteins as microarrays for high-throughput function determination. Science 289(5485): 1760-1763
33. Zhou Y, Liu AL, WangW, Du GH (2008) Using the protein chip to screen agonists and antagonists of the androgen receptor. J Biomol Screen 13(4):276-284. doi:10.1177/1087057108315881 (Pubitemid 351442759)
34. Li T, Liu DJ, Wang ZX (2010) Screening kinase inhibitors with a microarray-based fluorescent and resonance light scattering assay. Anal Chem 82(7):3067-3072. doi:10.1021/ac902804h
35. Zhou Y, Du GH, Geng MY, Lu ZH (2006) Rapid detection of anabolic steroids in urine by protein arrays. Int J Sports Med 27 (7):526-532. doi:10.1055/s-2005-865824 (Pubitemid 44047987)
36. Gao F, Du GH (2006) Application of chemical arrays in screening elastase inhibitors. Comb Chem High Throughput Screen 9 (5):381-388. doi:10.2174/ 138620706777452393 (Pubitemid 43830731)
37. Kawate H, Takayanagi R (2011) Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. Clin Interv Aging 6 (1):151-160. doi:10.2147/CIA.S15711
38. He L, Xiang H, Zhang LY, Tian WS, He HH (2005) Novel estrogen receptor ligands and their structure-activity relationship evaluated by scintillation proximity assay for high-throughput screening. Drug Dev Res 64(4):203-212. doi:10.1002/ddr.10435 (Pubitemid 41098361)
39. Fitzpatrick SL, Berrodin TJ, Jenkins SF, Sindoni DM, Deecher DC, Frail DE (1999) Effect of estrogen agonists and antagonists on induction of progesterone receptor in a rat hypothalamic cell line. Endocrinology 140(9):3928-3937. doi:10.1210/en.140.9.3928 (Pubitemid 30647086)
40. Shen ES, Meade EH, Perez MC, Deecher DC, Negro-Vilar A, Lopez FJ (1998) Expression of functional estrogen receptors and galanin messenger ribonucleic acid in immortalized luteinizing hormone-releasing hormone neurons: estrogenic control of galanin gene expression. Endocrinology 139(3):939-948. doi:10.1210/en.139.3.939 (Pubitemid 28510108)
41. Bolger R, Wiese TE, Ervin K, Nestich S, Checovich W (1998) Rapid screening of environmental chemicals for estrogen receptor binding capacity. Environ Health Perspect 106(9):551-557. doi:10.1289/ehp.98106551 (Pubitemid 28495430)
42. Liu H, Park WC, Bentrem DJ, McKian KP, De los Reyes A, Loweth JA, Schafer JM, Zapf JW, Jordan VC (2002) Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells. J Biol Chem 277(11):9189-9198. doi:10.1074/jbc.M108335200 (Pubitemid 34952998)
43. Gruschke A, Kuhl H (2001) Validity of radioimmunological methods for determining free testosterone in serum. Fertil Steril 76 (3):576-582. doi:10.1016/s0015-0282(01)01939-2
44. Mitchell P (2002) A perspective on protein microarrays. Nat Biotechnol 20(3):225-229. doi:10.1038/nbt0302-225 (Pubitemid 34205415)
45. K-i O, Fukushima T, Santa T, Waizumi N, Tokuyama H, Maeda M, Imai K (2002) Estrogen receptor binding assay method for endocrine disruptors using fluorescence polarization. Anal Chem 74 (17):4391-4396. doi:10.1021/ac020088u (Pubitemid 35006426)
46. Lin S, Bock CL, Gardner DB, Webster JC, Favata MF, Trzaskos JM, Oldenburg KR (2002) A high-throughput fluorescent polarization assay for nuclear receptor binding utilizing crude receptor extract. Anal Biochem 300(1):15-21 (Pubitemid 34066799)
47. Ran Lee J, Choi J, Ja Choi M (2001) Fluorescein labeling of estrogen for application of fluorescence polarization binding assays for antibody and receptor. Microchem J 70(3):229-238. doi:10.1016/S0026-265X(01)00137-0
48. Seifert M, Haindl S, Hock B (1999) Development of an enzyme linked receptor assay (ELRA) for estrogens and xenoestrogens. Anal Chim Acta 386(3):191-199. doi:10.1016/s0003-2670(99) 00044-6 (Pubitemid 29141472)
49. Klinge CM, Traish AM, Bambara RA, Hilf R (1996) Dissociation of 4-hydroxytamoxifen, but not estradiol or tamoxifen aziridine, from the estrogen receptor as the receptor binds estrogen response element DNA. J Steroid Biochem Mol Biol 57(1-2):51-66. doi:10.1016/0960-0760(95)00246-4 (Pubitemid 26148938)
50. Hock B, Seifert M, Kramer K (2002) Engineering receptors and antibodies for biosensors. Biosens Bioelectron 17(3):239-249. doi:10.1016/s0956-5663(01) 00267-6 (Pubitemid 34142605)
51. Toran-Allerand CD, Guan XP, MacLusky NJ, Horvath TL, Diano S, Singh M, Connolly ES, Nethrapalli IS, Tinnikov AA (2002) ER-X: a novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J Neurosci 22(19):8391-8401 (Pubitemid 35387579)
52. Gale WL, Patino R, Maule AG (2004) Interaction of xenobiotics with estrogen receptors alpha and beta and a putative plasma sex hormone-binding globulin from channel catfish (Ictalurus punctatus). Gen Comp Endocrinol 136(3):338-345. doi:10.1016/j.ygcen.2004.01.009 (Pubitemid 38479631)
53. Elbs M, Brock R (2003) Determination of binding constants on microarrays with confocal fluorescence detection. Anal Chem 75 (18):4793-4800. doi:10.1021/ac034381l (Pubitemid 37139780)